
グループ: Randox

カタログの抜粋

SUPERIOR PERFORMANCE & UNIQUE TESTS DESIGNED TO MEET THE NEEDS OF YOUR LABORATORY 1
カタログの1ページ目を開く
HIGH PERFORMANCE & UNIQUE TESTS Cardiology and Lipids | Diabetes | Renal Function | Antioxidants | Clinical Chemistry 2
カタログの2ページ目を開く
RENAL FUNCTION CLINICAL CHEMISTRY UNIQUE FEATURE NICHE PRODUCT When you see this symbol you will know that this feature is unique to the Randox product When you see this symbol you will know that Randox have one of the only automated biochemistry assays available on the market
カタログの3ページ目を開く
Benefits of Randox Reagents Randox offers an extensive range of third party diagnostic reagents which are internationally recognised as being of the highest quality; producing accurate and precise results. We have an extensive test menu of over 100 assays, covering over 100 disease markers including: antioxidants, diabetes, cardiology & lipid testing, specific proteins, therapeutic drug monitoring and veterinary testing. A wide range of formats and methods are available providing greater flexibility and choice for any laboratory size. In addition to flexible pack sizes and a comprehensive...
カタログの4ページ目を開く
CARDIOLOGY & LIPIDS Lipoprotein (a) | Small Dense LDL Cholesterol (sdLDL - C) | Homocysteine Apolipoprotein C - II | Apolipoprotein C - III | Apolipoprotein E 02
カタログの5ページ目を開く
Lipoprotein(a) (Lp(a)) Elevated levels of Lipoprotein(a) (Lp(a)), are considered to be both a causal risk factor and independent genetic marker of atherosclerotic disorders. The major challenge associated with Lp(a) measurement is the size variation of the apo(a) molecule within Lp(a). Dependent upon the size of the apo(a) in the assay calibrator, many assays under or overestimate apo(a) size in the patient sample. Numerous commercially available products suffer from apo(a) size related bias, resulting in an over estimation of Lp(a) in samples with large apo(a) molecules and an under...
カタログの6ページ目を開く
Small - dense LDL (Low Density Lipoprotein) Cholesterol (sdLDL - C) Small - dense LDL Cholesterol (sdLDL - C) is a subtype of LDL cholesterol. All LDL transports triglycerides and cholesterol to bodily tissues but their atherogenicity varies according to size. Smaller particles such as sdLDL - C can permeate the inner arterial wall more readily and are more susceptible to oxidation, making sdLDL - C particularly atherogenic. Research has found that individuals with a predominance of sdLDL - C have a three - fold increased risk of myocardial infarction, making sdLDL - C measurement extremely...
カタログの7ページ目を開く
Apolipoprotein C - II Apolipoprotein C - II (Apo C - II) is an amino acid protein synthesised mainly in the liver and to a lesser extent in the intestine. Apo C-II acts as a co - factor for lipoprotein lipase; an enzyme that hydrolyses triglycerides in chylomicrons and VLDL - C. Patients have been identified with hypertriglyceridemia due to a deficiency in Apo C - II which leads to an increased risk of the patient developing coronary artery disease. Additional disease states associated with Apo C - II deficiency include chylomicronemia, xanthomas and recurrent pancreatitis. S Indicates...
カタログの8ページ目を開く
Apolipoprotein E Apolipoprotein E (Apo E) is an amino acid protein synthesised mainly in the liver but also in the brain, spleen, lungs, adrenals, ovaries, kidneys, muscle cells and in macrophages. The polymorphism of Apo E has been implicated in several diseases including cardiovascular disease and neurodegenerative diseases such as Alzheimer’s. Apo E deficiency causes high serum cholesterol and triglyceride levels and leads to premature atherosclerosis. A number of factors can affect Apo E concentrations including: genetic polymorphisms, oral contraceptive intake, puberty, BMI and age. S...
カタログの9ページ目を開く
DIABETES Fructosamine | Non - Esterified Fatty Acids (NEFA) | D - 3 - Hydroxybutyrate (Ranbut) 07
カタログの10ページ目を開く
(Glycated Serum Protein) Fructosamine is a mid - term indicator of diabetic control as it can provide information on a person’s average blood glucose levels over the preceding 14 - 21 days. After commencing therapy, fructosamine level decrease earlier (within a week) than HbA1c (after 4 - 8 weeks) and so, it is often used to evaluate the effectiveness of medication changes and to monitor the treatment of gestational diabetes. Fructosamine is also particularly useful in situations where HbA1c cannot be reliably measured when individuals have, for example: haemolytic anaemia, thalassemia or...
カタログの11ページ目を開く
Randox D-3-Hydroxybutyrate (Ranbut) D - 3 - Hydroxybutyrate is the most sensitive ketone for the diagnosis of ketosis, in particular diabetic ketoacidosis. Ketosis, a metabolic process, occurs when the body switches from glucose to predominantly fat metabolism for energy production when carbohydrate availability reaches low levels. Metabolism of fatty acids in the liver results in the production of 3 ketones: acetone, acetoacetate and D - 3 - Hydroxybutyrate. Levels of ketone bodies in the blood are elevated (ketosis) when synthesis exceeds breakdown. Superior methodology when compared to...
カタログの12ページ目を開く
RENAL FUNCTION Liquid Enzymatic Creatinine | Microalbumin 10
カタログの13ページ目を開く
Liquid Enzymatic Creatinine Creatinine clearance in the kidneys provides a measure of the Glomerular Filtration Rate (GFR) and is the standard marker for renal function. The enzymatic method of Creatinine measurement displays several advantages over the JAFFE method: highly specific, no interferences from endogenous creatinine as it is not involved in the pathway and eliminates the requirement for urea determination. Systemic errors from JAFFE creatinine provides unreliable renal function estimates, resulting in the risk of incorrect drug dosage adjustments, misclassification in Chronic...
カタログの14ページ目を開く
Microalbumin The Microalbumin assay detects very low levels of albumin in urine. The detection of albumin in urine can be an indicator of kidney injury which can result in irreversible damage if left untreated. Low albumin concentrations in urine (20 - 200mg/ day) is the earliest marker of renal damage and therefore enables preventative measures to be taken. Microalbumin testing can identify individuals with diabetic nephropathy approximately 5 - 10 years earlier than proteinuria tests helping reduce the incidence of end stage renal disease. Standard supplied with kit simplifying the...
カタログの15ページ目を開くRandox Laboratories/ランドックスのすべてのカタログと技術パンフレット
-
LT735 Vivalytic Overview
32 ページ
-
Acusera New Controls
8 ページ
-
Acusera 24.7
24 ページ
-
Acusera Third Party Controls
108 ページ
-
Acusera SMART Controls
12 ページ
-
Company Overview
40 ページ
-
Reagents Brochure
64 ページ
-
sdLDL-C
8 ページ
-
RX modena
20 ページ
-
RX misano
20 ページ
-
RX Daytona Plus
20 ページ
-
Rx Imola
20 ページ
-
RX Monaco
20 ページ
-
2024 Product List
64 ページ
-
VeraSTAT-V
16 ページ
-
LT033 RIQAS Explained
64 ページ
-
VERASTAT
16 ページ
-
Endocrine Array
4 ページ
-
Cerebral Arrays
4 ページ
-
Thyroid Arrays
4 ページ
-
Basic QC Stastics
8 ページ
-
Commutability Guide
4 ページ
-
Qnostics
52 ページ
-
Adiponectin LT519
28 ページ
-
Specific Proteins
40 ページ
-
Linearity sets
12 ページ
-
Antioxidants
16 ページ
-
Diabetes Portfolio
28 ページ
-
Total Bile Acids
4 ページ
-
VIVALYTIC
30 ページ
-
RANDOX DISCOVERY
36 ページ
-
HbA1c
2 ページ
-
Preparing QC
1 ページ
-
Point of Care Testing
12 ページ
-
Guide to running QC
1 ページ
-
Tumour Marker Arrays
4 ページ
-
LT169 Cardiac Array
4 ページ
カタログアーカイブ
-
ACUSERA
108 ページ
-
Evidence Evolution
28 ページ
-
Evidence
16 ページ
-
STI Multiplex Array
8 ページ
-
Molecular Testing
16 ページ
-
Evidence Investigator
20 ページ
-
Fertility Array
4 ページ
-
Rx Daytona
16 ページ
-
Evidence Investigator
16 ページ
-
Evidence
16 ページ